BIIB - BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. | Benzinga
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
- Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)?
- Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive?
- Did you lose money in your investment in Biogen Inc.?
- Do you want to discuss your rights?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Biogen Inc. ("Biogen" or the "Company") (NASDAQ:BIIB) between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Colorado and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
If you purchased or acquired Biogen securities, and/or would like to discuss your legal rights and options please visit Biogen Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide. The Company's products include, among others, Leqembi and Aduhelm for the treatment of Alzheimer's disease ("AD"), as well as various drugs for the treatment ...
BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.>Full story available on Benzinga.com